Najat Khan is Chief Executive Officer and President of Recursion Pharmaceuticals, Inc. (RXRX). The company reported total compensation of $5,349,065 for fiscal year 2025.
| Salary | $600,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $1,944,547 |
| Option awards | $2,501,058 |
| Non-equity incentive plan | $256,777 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $46,683 |
| Total | $5,349,065 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Recursion Pharmaceuticals, Inc. filed April 30, 2026, accession 0001601830-26-000065.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer and President | $600,000 | $0 | $1,944,547 | $2,501,058 | $256,777 | $0 | $46,683 | $5,349,065 |
| FY2024 | Chief R&D and Chief Commercial Officer | $285,000 | $500,000 | $3,647,774 | $4,592,021 | $115,824 | — | $54,185 | $9,194,805 |
Totals as disclosed in each year's own compensation disclosure for Recursion Pharmaceuticals, Inc..
| Peer-group chief executive median | $6,392,236 |
|---|---|
| Difference from that median | $-1,043,171 |
| Percentile within the disclosed peer group | 38th |
| Peers with a disclosed figure | 16 |
Medians and percentiles are computed across the peer group Recursion Pharmaceuticals, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Christopher Gibson | Former Chief Executive Officer and President and current Chair of the Board | $9,607,508 |
| Najat Khan this page | Chief Executive Officer and President | $5,349,065 |
| Ben Taylor | Chief Financial Officer and President of Recursion UK | $1,328,483 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Recursion Pharmaceuticals, Inc. compensation brief.
Najat Khan's compensation sits inside Recursion Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The Recursion Pharmaceuticals, Inc. (RXRX) compensation brief